17 Drydock Avenue, Suite #17-401, Boston, MA 02210
Aktis Oncology, Inc. is incorporated under the laws of the State of Delaware. The company was founded in August 2020.
Aktis Oncology, Inc. began trading on the NASDAQ Global Select Market on January 9, 2026.
The Company’s common stock is traded on the NASDAQ Global Select Market under the trading symbol AKTS.
The Company’s CUSIP number is 01021M 104.
Shares of Aktis Oncology’s common stock can be purchased by contacting a securities broker of your choice.
The Company’s fiscal year-end is December 31st.
Aktis Oncology’s transfer agent is Computershare Trust Company, N.A. You can find more information by contacting Computershare Trust Company, N.A. located at 150 Royall Street, Canton, MA 02021.
If you have misplaced your share certificates, please contact Aktis Oncology’s transfer agent, Computershare Trust Company, N.A. There may be a fee for replacing lost share certificates.
If the shares are held in your name, you must contact Aktis Oncology’s transfer agent, Computershare Trust Company, N.A. If the shares are held in street name, you must contact your broker to update your address.
The Company currently does not pay dividends or offer a dividend reinvestment program.
The Company currently does not have a direct stock purchase plan.
Deloitte & Touche LLP
Paul Hastings LLP
Aktis Oncology press releases and financial reports can be viewed in the “Investors” section of our corporate website.
Please visit the "Investors" section of Aktis Oncology’s corporate website to be added to the Company’s distribution list.
Filings may be accessed directly from the SEC website at https://www.sec.gov/ or can be viewed on the “SEC Filings” section of our “Investors” site.
Aktis Oncology’s Leadership Team and Board of Directors can be viewed at https://www.aktisoncology.com/our-team/.
Please email investor-related questions to investors@aktisoncology.com.
The whistleblower hotline can be accessed at 833-364-0919.